Skip to main content

Table 1 Characteristics of cardiovascular risk clinical prediction rules (CPRs)

From: Predictors for independent external validation of cardiovascular risk clinical prediction rules: Cox proportional hazards regression analyses

 

CPRs with an independent external validation, n = 29

CPRs with no independent external validation, n = 96

All cardiovascular risk CPRs, n = 125

A. CPR derivation

1. Study design, n (%)*

 Cohort

25 (89.3)

85 (88.5)

110 (88.7)

 Case-control

3 (10.7)

11 (11.5)

14 (11.3)

2. Geographic location, n (%)

 USA

20 (69.0)

23 (24.0)

43 (34.4)

 Continental Europe

4 (13.8)

25 (26.0)

29 (23.2)

 UK

2 (6.9)

10 (10.4)

12 (9.6)

 Asia

0 (0.0)

19 (19.8)

19 (15.2)

 Other

0 (0.0)

10 (10.4)

10 (8.0)

 Multiple countries

3 (10.3)

9 (9.4)

12 (9.6)

3. Sample size, median (IQR)*

6032 (5277–19,306)

5206 (2721–12,299.5)

5722.5 (3396–12,711.5)

4. Number of predictors, median (IQR)**

8 (7–9)

8 (6–9)

8 (6–9)

5. Presentation format, n (%)

 User-friendly

15 (51.7)

37 (38.5)

52 (41.6)

 Not user-friendly

14 (48.3)

59 (61.5)

73 (58.4)

6. Validation in derivation, n (%)

 External

1 (3.5)

18 (18.8)

19 (15.2)

 Internal

9 (31.0)

23 (24.0)

32 (25.6)

 None

19 (65.5)

55 (57.3)

74 (59.2)

B. Reporting and publication

1. Description of participants, n (%)

 Clear

15 (51.7)

46 (47.9)

61 (48.8)

 Unclear

14 (42.3)

50 (52.1)

64 (51.2)

2. Description of predictors, n (%)

 Clear

11 (37.9)

54 (56.3)

65 (52.0)

 Unclear

18 (62.1)

42 (43.8)

60 (48.0)

3. Description of outcomes, n (%)

 Clear

8 (27.6)

40 (41.7)

48 (38.4)

 Unclear

21 (72.4)

56 (58.3)

77 (61.6)

4. Performance measure, n (%)

 Reported

16 (55.2)

67 (69.8)

83 (66.4)

 Not reported

13 (44.8)

29 (30.2)

42 (33.6)

5. Information for risk calculation, n (%)

 Reported

24 (82.8)

54 (56.3)

78 (62.4)

 Not reported

5 (17.2)

42 (43.8)

47 (37.6)

6. Impact factor, median (IQR)

15.1 (4.3–17.2)

3.9 (3.1–7.1)

4.3 (3.2–15.1)

  1. *Could not be determined for Adult Treatment Panel III model (reference)
  2. **Could not be determined for CHD prevention model by McNeil et al. (reference)